Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Combination Treatment with Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for High-Risk and Steroid-Refractory Acute GVHD

NCT05333029 is registered in ClinicalTrials.gov with Molly Gallogly as lead sponsor.

NCT NCT05333029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05333029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Combination Treatment with Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for High-Risk and Steroid-Refractory Acute GVHD
Lead sponsor
Molly Gallogly
Phase
Phase 2
Overall status
Withdrawn
Start date
October 1, 2024
Completion date
June 1, 2025
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft versus host disease